Yatharth Q1FY27: consolidated PAT +8% YoY as margins compress despite 51% revenue surge

Yatharth Hospital's consolidated Q1 FY27 revenue rose 51.5% YoY (14.96% QoQ) to Rs392.7 Cr, comfortably ahead of management's own FY27 guidance to "surpass" FY26's 36% YoY growth, and above the Rs314 Cr Street estimate from Uniresearch/Univest. Consolidated PAT of Rs45.4 Cr grew just 8.0% YoY (1.6% QoQ) and came in well below the Street's Rs59 Cr PAT estimate -- a clear miss on the bottom line even as revenue beat. No exceptional items feature in either period, so the 8% YoY PAT growth is a clean, unadjusted number, not distorted by one-offs. The gap between revenue and profit growth traces to margin compression across both operating and financing lines. Consolidated OPM (EBITDA margin) fell to 23.35% from 25.02% a year ago -- slipping below management's guided 24-25% band that was reaffirmed just last quarter -- while NPM dropped more sharply to 11.44% from 15.74% YoY (and from 12.82% last quarter). Finance costs jumped roughly 34x YoY to Rs6.59 Cr and depreciation rose 89% to Rs28.24 Cr, both consequences of debt-funded capacity additions, including the Rs100 Cr acquisition of an under-construction 250-bed Gurugram hospital completed June 12, 2026. Employee costs also grew 61.7% YoY to Rs77.91 Cr as the company staffed up ahead of ramp-up. Standalone PAT grew only 3.9% YoY to Rs28.17 Cr, versus consolidated's 8.0%, confirming that most of the incremental profit and nearly all of the revenue growth is coming from subsidiaries and newer hospital assets rather than the core standalone entity. Consolidated PAT attributable to owners was Rs47.06 Cr (EPS Rs4.88, +12.2% YoY), higher than total group PAT of Rs45.42 Cr because non-controlling interests posted a Rs1.64 Cr loss for the quarter -- a detail worth noting when reconciling the two profit figures. Alongside results, the board declared a first interim FY27 dividend of Rs0.50/share (record date August 14, 2026) and approved a new employee stock option scheme covering 2.5 lakh shares, both signalling confidence even as near-term margins soften. No separate management press release was available in the record for this quarter. The quarter sets up a key test for the next two-to-three quarters: whether OPM stabilizes and recovers toward the guided 24-25% band as the newly acquired Gurugram asset and other greenfield capacity ramp up, or whether the elevated finance-cost and depreciation base -- from an expansion pace management has pegged at roughly 70% acquisitions/30% greenfield toward a 5,000-bed target -- keeps compressing profitability even as revenue growth stays strong.